Description
IQVIA Holdings’ $17.5 Billion Revenue Outlook Sparks a Bigger Growth Question!
Iqvia Holdings Inc. reported third quarter 2026 results demonstrating growth across its key metrics, though with some operational and financial nuances that warrant a balanced evaluation. The company achieved total reported revenue of $4.43 billion, reflecting an 8% year-over-year increase and 8.6% growth on a constant currency basis. Organic revenue growth accelerated to approximately 6%, more than doubling the pace from the prior year. This advance was driven by increases in both Clinical (R&D Solutions) and Commercial Solutions segments, with Clinical Solutions revenue growing 8.7% (7% organically) and Commercial Solutions up 6.9% (4% organically). Adjusted EBITDA expanded by 8.7% year over year to $1.008 billion for the quarter, alongside a 20-basis-point margin increase, marking the second consecutive quarter of margin expansion. Adjusted diluted earnings per share rose 11.3%, exceeding the high end of guidance and reflecting operational strength.



